# Spruce Street Capital LP: Form 13F holdings

An institutional investment manager in NEW YORK, NY. SEC CIK 2050194.

- Quarter ended: 2026-06-30
- Filed: 2026-08-13
- Reported value: $509.7m
- Positions: 30 (30 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/2050194/000205019426000005/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| KINIKSA PHARMACEUTICALS INTL | ORD SHS CL A | $58.7m | 11.5% | 918,070 |  | Added +157,007 |
| [RELAY THERAPEUTICS INC (RLAY)](/companies/rlay.md) | COM | $55.8m | 11.0% | 2,984,125 |  | Unchanged |
| [LB PHARMACEUTICALS INC (LBRX)](/companies/lbrx.md) | COM SHS | $44.7m | 8.8% | 1,376,159 |  | Unchanged |
| [RELMADA THERAPEUTICS INC (RLMD)](/companies/rlmd.md) | COM | $44.2m | 8.7% | 6,391,328 |  | Added +129,214 |
| [ALTO NEUROSCIENCE INC (ANRO)](/companies/anro.md) | COM SHS | $35.7m | 7.0% | 1,353,047 |  | Added +27,837 |
| [DIANTHUS THERAPEUTICS INC (DNTH)](/companies/dnth.md) | COM | $34.6m | 6.8% | 354,816 |  | Reduced −18,458 |
| ALKERMES PLC | SHS | $28.5m | 5.6% | 543,876 |  | Added +225,884 |
| [SAVARA INC (SVRA)](/companies/svra.md) | COM | $21.3m | 4.2% | 3,452,576 |  | Added +69,401 |
| [VAXCYTE INC (PCVX)](/companies/pcvx.md) | COM | $17.8m | 3.5% | 306,047 |  | Added +60,338 |
| [ENLIVEN THERAPEUTICS INC (ELVN)](/companies/elvn.md) | COM | $16.7m | 3.3% | 329,006 |  | Unchanged |
| [ENANTA PHARMACEUTICALS INC (ENTA)](/companies/enta.md) | COM | $15.9m | 3.1% | 1,088,731 |  | Added +156,133 |
| [PERSPECTIVE THERAPEUTICS INC (CATX)](/companies/catx.md) | COM NEW | $12.6m | 2.5% | 3,693,931 |  | Added +1,066,824 |
| INFLARX NV | COM | $12.0m | 2.4% | 5,352,198 |  | New +5,352,198 |
| [SURROZEN INC (SRZN)](/companies/srzn.md) | COM NEW | $11.2m | 2.2% | 432,040 |  | Unchanged |
| [ALUMIS INC (ALMS)](/companies/alms.md) | COM | $11.0m | 2.2% | 392,574 |  | Unchanged |
| [CENTURY THERAPEUTICS INC (IPSC)](/companies/ipsc.md) | COM | $9.9m | 2.0% | 4,059,054 |  | Unchanged |
| [MINERVA NEUROSCIENCES INC (NERV)](/companies/nerv.md) | COM NEW | $9.2m | 1.8% | 1,655,500 |  | Unchanged |
| [SAB BIOTHERAPEUTICS INC (SABS)](/companies/sabs.md) | COM NEW | $8.6m | 1.7% | 2,198,502 |  | Unchanged |
| [AN2 THERAPEUTICS INC (ANTX)](/companies/antx.md) | COM | $8.0m | 1.6% | 1,661,073 |  | Unchanged |
| [ERASCA INC (ERAS)](/companies/eras.md) | COM | $7.7m | 1.5% | 422,543 |  | Unchanged |
| [INHIBIKASE THERAPEUTICS INC (IKT)](/companies/ikt.md) | COM NEW | $7.3m | 1.4% | 3,581,603 |  | Unchanged |
| RESEARCH ALLIANCE CORP III | ORD SHS CL A | $5.3m | 1.0% | 500,000 |  | New +500,000 |
| HELIX ACQUISITION CORP III | USD CL A ORD SHS | $5.3m | 1.0% | 500,000 |  | Unchanged |
| [ZAI LAB LTD (ZLAB)](/companies/zlab.md) | ADR | $5.3m | 1.0% | 279,110 |  | New +279,110 |
| [ACHIEVE LIFE SCIENCE INC (ACHV)](/companies/achv.md) | COM | $4.8m | 0.9% | 736,637 |  | New +736,637 |
| [LEXEO THERAPEUTICS INC (LXEO)](/companies/lxeo.md) | COM | $4.3m | 0.8% | 928,593 |  | Unchanged |
| [ALECTOR INC (ALEC)](/companies/alec.md) | COM | $4.2m | 0.8% | 2,101,068 |  | Unchanged |
| [LEONABIO INC (LONA)](/companies/lona.md) | COM | $3.6m | 0.7% | 393,701 |  | Unchanged |
| [CORVUS PHARMACEUTICALS INC (CRVS)](/companies/crvs.md) | COM | $3.5m | 0.7% | 231,585 |  | Unchanged |
| JATT II ACQUISITION CORP | ORD SHS | $1.8m | 0.4% | 160,000 |  | New +160,000 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| CENTESSA PHARMACEUTICALS | SPONSORED ADS | $0 | 0.0% | 0 |  | Sold out −489,849 |
| KALVISTA PHARMACEUTICALS | COM | $0 | 0.0% | 0 |  | Sold out −897,681 |
| [MAZE THERAPEUTICS INC (MAZE)](/companies/maze.md) | COM | $0 | 0.0% | 0 |  | Sold out −200,000 |

Source: SEC EDGAR, Form 13F-HR, accession 0002050194-26-000005. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.